Opinion

Video

Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.

  1. The MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice?
  2. When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
5 experts in this video
Related Content
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Ambulatory chemotherapy
June 9th 2025

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

Molecular biologist holding blood sample for EGFR mutation test for the diagnosis of lung disease. Epidermal Growth Factor Receptor.
June 4th 2025

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

Luke Halpern, Assistant Editor
Image credit: catalin | stock.adobe.com
Published: June 3rd 2025 | Updated: June 11th 2025

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Joshua Sabari, MD Kennedy Ferruggia, Assistant Editor